Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.54.
Several research firms recently issued reports on INO. Maxim Group restated a “buy” rating and issued a $8.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, April 3rd. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, March 22nd. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Thursday, February 7th. Finally, BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 3rd.
A number of hedge funds have recently added to or reduced their stakes in the stock. Jefferies Group LLC acquired a new position in Inovio Pharmaceuticals in the first quarter valued at $106,000. Geode Capital Management LLC increased its stake in Inovio Pharmaceuticals by 12.7% in the first quarter. Geode Capital Management LLC now owns 1,131,213 shares of the biopharmaceutical company’s stock valued at $4,219,000 after purchasing an additional 127,118 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Inovio Pharmaceuticals by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 502,380 shares of the biopharmaceutical company’s stock valued at $1,874,000 after purchasing an additional 11,008 shares in the last quarter. Renaissance Technologies LLC increased its stake in Inovio Pharmaceuticals by 68.3% in the first quarter. Renaissance Technologies LLC now owns 564,281 shares of the biopharmaceutical company’s stock valued at $2,105,000 after purchasing an additional 229,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Inovio Pharmaceuticals by 58.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 395,399 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 145,300 shares in the last quarter. Institutional investors and hedge funds own 40.50% of the company’s stock.
Shares of NASDAQ:INO opened at $3.49 on Thursday. The firm has a market cap of $349.98 million, a PE ratio of -3.32 and a beta of 1.70. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02. Inovio Pharmaceuticals has a 52 week low of $3.02 and a 52 week high of $6.30.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $4.44 million. Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. Equities analysts anticipate that Inovio Pharmaceuticals will post -0.99 earnings per share for the current year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: Why investors pay attention to retained earnings
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.